Insider Transactions in Q1 2021 at Sangamo Therapeutics, Inc (SGMO)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 25
2021
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
345
-0.84%
|
$4,140
$12.27 P/Share
|
|
Mar 23
2021
|
Gary Loeb EVP, General Counsel & Sec. |
SELL
Open market or private sale
|
Direct |
17,524
-6.06%
|
$227,812
$13.15 P/Share
|
|
Mar 23
2021
|
Gary Loeb EVP, General Counsel & Sec. |
BUY
Exercise of conversion of derivative security
|
Direct |
11,981
+10.63%
|
$131,791
$11.02 P/Share
|
|
Feb 25
2021
|
Robert Carey |
BUY
Grant, award, or other acquisition
|
Direct |
8,200
+26.11%
|
-
|
|
Feb 25
2021
|
Kenneth J. Hillan |
BUY
Grant, award, or other acquisition
|
Direct |
8,200
+26.11%
|
-
|
|
Feb 25
2021
|
John Markels |
BUY
Grant, award, or other acquisition
|
Direct |
8,200
+38.32%
|
-
|
|
Feb 25
2021
|
James R Meyers |
BUY
Grant, award, or other acquisition
|
Direct |
8,200
+26.11%
|
-
|
|
Feb 25
2021
|
H Stewart Parker |
BUY
Grant, award, or other acquisition
|
Direct |
8,200
+20.81%
|
-
|
|
Feb 25
2021
|
Saira Ramasastry Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,200
+26.11%
|
-
|
|
Feb 25
2021
|
Karen L. Smith |
BUY
Grant, award, or other acquisition
|
Direct |
8,200
+24.19%
|
-
|
|
Feb 25
2021
|
Joseph S Zakrzewski Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,200
+14.54%
|
-
|
|
Feb 25
2021
|
Sandy Macrae PRESIDENT, CEO AND DIRECTOR |
BUY
Grant, award, or other acquisition
|
Direct |
138,375
+28.51%
|
-
|
|
Feb 25
2021
|
Sandy Macrae PRESIDENT, CEO AND DIRECTOR |
SELL
Payment of exercise price or tax liability
|
Direct |
35,311
-14.47%
|
$388,421
$11.19 P/Share
|
|
Feb 25
2021
|
Gary Loeb EVP, General Counsel & Sec. |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+33.14%
|
-
|
|
Feb 25
2021
|
Gary Loeb EVP, General Counsel & Sec. |
SELL
Payment of exercise price or tax liability
|
Direct |
5,762
-11.4%
|
$63,382
$11.19 P/Share
|
|
Feb 25
2021
|
David Mark Mc Clung EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+22.22%
|
-
|
|
Feb 25
2021
|
Rolf Andrew Ramelmeier EVP, Technical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+28.94%
|
-
|
|
Feb 25
2021
|
Rolf Andrew Ramelmeier EVP, Technical Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
7,779
-11.79%
|
$85,569
$11.19 P/Share
|
|
Feb 25
2021
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,750
+25.05%
|
-
|
|
Feb 25
2021
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,863
-6.37%
|
$20,493
$11.19 P/Share
|
|
Feb 12
2021
|
Robert J. Schott SVP, Head of Development |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+50.0%
|
-
|
|
Jan 24
2021
|
Sandy Macrae PRESIDENT, CEO AND DIRECTOR |
SELL
Payment of exercise price or tax liability
|
Direct |
3,977
-1.6%
|
$55,678
$14.95 P/Share
|